Dynavax Technologies Corporation Stock News

The average of price targets set by Wall Street analysts indicates a potential upside of 103.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionab

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Weyerhaeuser Co (NYSE: WY) a lot. When asked about Lockheed Martin Corp (NYSE: LMT), he said, "People are worried about the Republi

With 2022 in the rearview mirror, it's time to hunt for solid, undervalued long-term stocks to buy. First, it's essential to define what is meant by long-term.

One of the more fun assignments at InvestorPlace is selecting the top small-cap stock picks for 2023. In this case, I've been chosen to provide readers with seven options for next year.

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothe

Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

HDSN, CWBC and DVAX made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2022.

Vaccine play Dynavax Technologies once again delivered stellar quarterly results after the bell on Thursday. Despite this, the stock continues to get a muted reaction from the investment community.

DVAX earnings call for the period ending September 30, 2022.